- In a paper published in the New
Zealand Medical Journal (Volume 113, Feb 11, 2000), environmental
scientist and long-time campaigner against soy-based infant formulas,
Dr Mike Fitzpatrick, has warned about the risk of thyroid disease
in infants fed soy formulas, high soy consumers and users of isoflavone
supplements:
"There is potential for certain individuals
to consume levels of isoflavones in the range that could have goitrogenic
effects. Most at risk appear to be infants fed soy formulas, followed
by high soy users and those using isoflavone supplements".
The report noted that infants fed soy formulas are
exposed to high levels of isoflavones, which are potent anti-thyroid
agents, and that the risks to normal growth and development were
significant. Fitzpatrick stated that thyroid problems due
to soy might not be recognised "due to difficulties in establishing
a cause and effect relationship" and noted that even experienced
soy researchers may be ignorant of the connection between isoflavones
and goitre. Fitzpatrick also rejected claims that there was
no evidence that isoflavones in soy formulas harmed infants
citing the reported cases of goitre that have occurred in infants
fed iodine sufficient soy formulas.
Fitzpatrick stated his support to the position of
the New Zealand Ministry of Health:
"MOH has found that infants with a history
of thyroid dysfunction should avoid soy formulas and soy milks.
Additionally, there is potential for isoflavone exposure to cause
chronic thyroid damage in all infants fed soy formulas"
Fitzpatrick stated that exposing infants to isoflavones
was unnecessary and that the risk of harm could be avoided if manufacturers
removed isoflavones from soy formulas. "In the interim"
he stated "it is appropriate for medical practitioners to monitor
the thyroid status of infants fed soy formulas"
Fitzpatrick also claimed that high soy consumers
and users of isoflavone supplements were also at risk of thyroid
disorders. He stated that the subtle effects of anti-thyroid
agents on thyroid function would most likely be evidenced as subclinical,
or even overt hypothyroidism.
Fitzpatrick also noted that a sporadic pattern of
soy use may also not be without risk since the resulting thyroid
stimulation parallels the classic method for inducing thyroid tumours
in laboratory animals. He recommended "a more cautionary
approach to the use of soy and isoflavone supplements".
Download the full paper
|